Restricted Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Pediatric B-Lineage Acute Lymphoblastic Leukemia Suggests Targetability with Therapeutic Monoclonal Antibodies

The future role of monoclonal antibody therapy in childhood acute leukaemias

(2012) Matthew Barth et al.   BRITISH JOURNAL OF HAEMATOLOGY

NKX2-1/TITF1/TTF-1-Induced ROR1 Is Required to Sustain EGFR Survival Signaling in Lung Adenocarcinoma

(2012) Tomoya Yamaguchi et al.   CANCER CELL

Targeting malignant B cells with an immunotoxin against ROR1

(2012) Sivasubramanian Baskar et al.   mAbs

ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth

(2012) Suping Zhang et al.   PLoS One

ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy

(2012) Guilly Rebagay et al.   Frontiers in Oncology

Ror1 Is a Pseudokinase That Is Crucial for Met-Driven Tumorigenesis

(2011) A. Gentile et al.   CANCER RESEARCH

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia

(2011) H. Elizabeth Broome et al.   LEUKEMIA RESEARCH

Mouse Resistin Modulates Adipogenesis and Glucose Uptake in 3T3-L1 Preadipocytes Through the ROR1 Receptor

(2011) Beatriz Sánchez-Solana et al.   MOLECULAR ENDOCRINOLOGY

Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies

(2011) Jiahui Yang et al.   PLoS One

The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor

(2010) M. Hudecek et al.   BLOOD

Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial

(2010) A. S. Wayne et al.   CLINICAL CANCER RESEARCH

ROR1 expression is not a unique marker of CLL

(2010) Gábor Barna et al.   HEMATOLOGICAL ONCOLOGY

Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia

(2010) R Handgretinger et al.   LEUKEMIA

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway

(2009) R. Lapalombella et al.   BLOOD

RNAi screen for rapid therapeutic target identification in leukemia patients

(2009) J. W. Tyner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia

(2008) S. Baskar et al.   CLINICAL CANCER RESEARCH

Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy

(2008) Amir H. DaneshManesh et al.   INTERNATIONAL JOURNAL OF CANCER

Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study

(2008) Elizabeth A. Raetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia

(2008) Mahdi Shabani et al.   LEUKEMIA & LYMPHOMA

Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a

(2008) T. Fukuda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA